Danaher (DHR) March 125 calls active after acquiring the biopharma business of GE Life Sciences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Danaher (DHR) PT Raised to $125 at Baird
February 26, 2019 9:15 AM ESTBaird analyst Richard Eastman raised the price target on Danaher (NYSE: DHR) to $125.00 (from $114.00) while maintaining an Outperform rating following the announced GE Biopharma acquisition. Eastman views the acquisition as attractive.
Adjusting for ~$1.4B in NPV tax benefits to DHR, the purchase price... More
Danaher (DHR) Announces Proposed $1.35B Common Share Offering; Announces Concurrent $1.35B Mandatory Convertible Preferred Share Offering
February 26, 2019 5:45 AM ESTDanaher Corporation (NYSE: DHR) announced today that it has commenced concurrent offerings of $1.35 billion of shares of common stock and $1.35 billion of shares of Series A Mandatory Convertible Preferred Stock, subject to market and other conditions (the offerings). Danaher expects to grant the underwriters separate 30-day options to purchase up to an additional $135 million of shares of common stock, and up to an additional $135 million of shares of mandatory convertible preferred... More
